AzTrials
AzTrials

RehabilitationNCT03722602

Body Composition of People After a Stroke

A study testing Standard rehabilitation after stroke in people with Rehabilitation and Stroke, run by University of Rzeszow at 1 site in Poland.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The study enabled assessment of changes in body mass composition, metabolic syndrome and lipid profile in patients after stroke, following rehabilitation in hospital. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Rehabilitation, Stroke, Body Composition
What is being tested?
Standard rehabilitation after stroke
Could I receive a placebo?
No, everyone receives an active treatment
How many people
100 participants
Where
1 sitePoland
Study dates
Jun 2015to Mar 2017
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Stroke experienced.
  • Ability to stand without assistance.
  • Ability to walk without aid.
  • No impairments in higher mental functions
  • Patient's informed, voluntary consent to participate in the study.

Who cannot join

  • Lack of patient's consent to participate in the study
  • Lack of ability to stand without assistance.
  • Ischemic lesion located in the cerebellum and brain stem.
  • Metal, electronic implants.
  • Epilepsy.
  • Pregnancy.
  • Menstruation, in females.
  • Limb injuries incurred following stroke onset, prior to the exam.

Trial locations and contacts

1 site in 1 country.

Poland1 site
  • University of Rzeszów

    Rzeszów, 35-205

Other trials in Poland

About this study

Official title: Effect of Rehabilitation on the Body Composition in Patients With Stroke

The study enabled assessment of changes in body mass composition, metabolic syndrome and lipid profile in patients after stroke, following rehabilitation in hospital.

Read the detailed description

Stroke is estimated to affect 24-54% of the global population and is one of the leading causes of death. According to World Health Organization over one billion people worldwide are overweight, and approximately 300 million people are obese. The main factors contributing to this situation include insufficient physical activity and unhealthy diet. Among the major consequences of obesity in adults one can distinguish metabolic syndrome and cardiovascular diseases.

Therefore, measurements were performed to identify changes in body mass composition (body fat, visceral fat level, muscle mass, total body water, metabolic syndrome, lipid profile) in subjects after stroke following rehabilitation at hospital.

The study was carried at the Clinical Rehabilitation Ward with Early Neurological Rehabilitation Unit, at the Clinical Hospital in Rzeszów, Poland. The measurements were performed from June 2015 to March 2017. During that time the total of 1,143 patients received treatment and rehabilitation at the clinic. These included 403 patients after stroke. The subjects were examined three times. In accordance with inclusion and exclusion criteria 128 subjects were qualified for the first exam. The second exam took into account 114 subjects and finally 100 patients with stroke participated in the third exam. The analyses took into account the data obtained from the 100 subjects who took part in all the exams. Body mass composition was assessed in all the subjects with Tanita MC 780 MA analyzer, whose operation is based on Bioelectrical impedance analysis (BIA). The subjects' height was measured with the stadiometer PORTSTAND 210. Rehabilitation outcome was assessed with Barthel index, Berg scale, Ashworth scale, Brunnström scale, Rankin scale and symmetry index for lower limb weight distribution (Ws).

In addition, waist and hip circumference were measured and WHR was calculated. The above parameters were assessed three times:

Exam I took place upon admission to hospital Exam II on the day the patient was discharged from hospital Exam III was performed 12 weeks after discharge from hospital during a follow-up visit.

The follow-up visit, 12 weeks after discharge from hospital, was meant to determine whether the effects of rehabilitation persisted for 12 weeks after discharge from hospital.

Other parameters examined included: LDL, HDL, total cholesterol, TG, atherogenic index, CRP, and serum glucose level. Blood for the tests was drawn from basilic vein by medical personnel at the Rehabilitation Clinic. The test was performed twice: upon admission to the Clinic and following 5-week rehabilitation at the hospital.

Being tested
Standard rehabilitation after stroke
Keywords
stroke, BMI, body composition, functional scales
Medical subject headings
Stroke

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Standard rehabilitation after strokeOther

    The program of the rehabilitation was designed specifically for each patient. It was prepared to match the patient's functional status and the defined goals. The subjects participated in exercise five days per week, for five weeks. During their stay at the Clinic, the patients took part in morning exercise and received individual practice, based on neuro-developmental treatment (Bobath concept), and proprioceptive neuromuscular facilitation (PNF) method, addressing the impaired motor abilities; if it was needed they also performed exercise based on equipment using biological feedback: Balance Trainer (static and dynamic parapodium) and Pablo system designed for upper limb training.

Study groups in NCT03722602
Study groupRoleWhat they receive
Rehabilitation groupExperimentalPatients with stroke receiving standard inpatient rehabilitation for five weeks
Receives: Other: Standard rehabilitation after stroke

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change Body composition assessment (fat mass, visceral fat level , muscle tissue, fat free mass , water content in the body) subjected to bioelectrical impedancy analysis - Tanita 780.

    Assessment of body composition (bioelectrical impedancy analysis - Tanita 780) Change from Baseline body composition at 5 weeks between baseline, after the end of protocol treatment, and 12 weeks after the end of the protocol treatment.

    Measured: at baseline, immediately after treatment completion, and 12 weeks after treatment completion

Secondary outcomes (15)
  1. Assessment of functional status was assessed using the Barthel Index. The subjects could score the maximum of 100 points.

    Activities of daily living were assessed using Barthel Index. The subjects could score the maximum of 100 points.

    A maximum of 100 points can be obtained on the Barthel scale. There are three assessment ranges: getting from 0 to 20 points. means total dependence, from 20 to 80 points. means that to some extent the patient needs help from others, and the assessment in the border is 80 to 100 points. means that with a little help the patient can function alone.

    0-20 points patient's condition "light" 21-85 points - "medium-heavy" patient condition 86-100 points - patient condition "very heavy"

    Measured: at baseline, immediately after treatment completion, and 12 weeks after treatment completion

  2. Balance was assessed using Berg Balance Scale (BBS)

    Balance was assessed using Berg balance scale (BBS)

    Berg Balance Scale

    Description:

    14-item scale designed to measure balance

    (1. Sitting to standing 2. Standing unsupported 3. Sitting unsupported 4. Standing to sitting 5. Transfers 6. Standing with eyes closed 7. Standing with feet together 8. Reaching forward with outstretched arm 9. Retrieving object from floor 10. Turning to look behind 11. Turning 360 degrees 12. Placing alternate foot on stool 13. Standing with one foot in front 14. Standing on one foot)

    Scoring: A five-point ordinal scale, ranging from 0-4. "0" indicates the lowest level of function and "4" the highest level of function. Score the LOWEST performance. Total Score = 56

    Interpretation: 41-56 = independent 21-40 = walking with assistance 0 -20 = wheelchair bound

    Measured: at baseline, immediately after treatment completion, and 12 weeks after treatment completion

  3. Assessment of muscle tone (spasticity) was examined with modified Ashworth scale.

    Increased muscle tone (spasticity) was examined with modified Ashworth scale. This is a six-point scale modified to include grade 1.

    0: No increase in muscle tone

    1. Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension 1+: Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM
    2. More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved
    3. Considerable increase in muscle tone, passive movement difficult
    4. Affected part(s) rigid in flexion or extension

    Measured: at baseline, immediately after treatment completion, and 12 weeks after treatment completion

  4. Assessment of paretic limb function was assessed using the Brunnström scale.

    Motor performance (function) of extremities was assessed using Brunnström scale. This is a six-point scale designed to assess performance (function) of paretic extremities

    Measured: at baseline, immediately after treatment completion, and 12 weeks after treatment completion

  5. Assessment of symmetry index for lower limb weight distribution

    Symmetry index for lower limb weight distribution (Ws) was calculated based on data obtained in tandem balance test, where the higher value was divided by the lower value. Normal index value, which was assumed in the range from 1.00 to 1.15, reflects the fact that weight is evenly distributed between legs, with permissible deviation up to 4-5 kilograms

    Measured: at baseline, immediately after treatment completion, and 12 weeks after treatment completion

  6. Assessment of disability level, using the modified Rankin scale (MRS)

    Assessment of disability using the modified Rankin scale (MRS)

    Score Description 0 - No symptoms at all

    1- No significant disability despite symptoms; able to carry out all usual duties and activities 2 - Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance 3 - Moderate disability; requiring some help, but able to walk without assistance 4 - Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance 5 - Severe disability; bedridden, incontinent and requiring constant nursing care and attention 6 - Dead TOTAL (0-6): _______

    Measured: at baseline, immediately after treatment completion, and 12 weeks after treatment completion

  7. Changes in blood parameter: HDL

    Blood for the tests was drawn from basilic vein by medical personnel at the Rehabilitation Clinic.

    HDL level:

    Men:

    Less than 35 mg / dL (0.9 mmol / L) high risk of heart disease.

    Women:

    Lower than 45 mg / dL (1.2 mmol / L) high risk of heart disease. 60 mg / dL (1.56 mmol / L) and above. High HDL cholesterol.

    Measured: at 5 weeks between baseline, after the end of protocol treatment,

  8. Changes in blood parameter: LDL

    Blood for the tests was drawn from basilic vein by medical personnel at the Rehabilitation Clinic.

    LDL level:

    Less than 100 mg / dL (2.6 mmol / L) Norm 100 - 129 mg / dL (2.63.34 mmol / L) Above the norm 130 - 159 mg / dL (3.36 - 4.13 mmol / L) Limit 160 - 189 mg / dL (4.14 - 4.90 mmol / L) High 190 mg / dL (4.91 mmol / L) and above Very high

    Measured: at 5 weeks between baseline, after the end of protocol treatment

  9. Changes in blood parameter: total cholesterol

    Blood for the tests was drawn from basilic vein by medical personnel at the Rehabilitation Clinic.

    Total Cholesterol level:

    Less than 200 mg / dL (5.17 mmol / L) Norm 200 - 239 mg / dL (5.17 - 6.18 mmol / L) Elevated level 240 mg / dL (6.21 mmol / L) High risk of heart disease

    Measured: at 5 weeks between baseline, after the end of protocol treatment

  10. Assessment of WHR

    The type of obesity is assessed with the so-called waist-to-hip ratio (WHR), which shows the proportion of waist circumference and hip circumference. WHR specifies the location of excessive fat and makes it possible to identify two main types of obesity: visceral obesity (characteristic for men), connected with accumulation of fat in the abdominal cavity and upper part of the body, and gynoid obesity (gluteal-femoral), more common in women.

    Measured: at 5 weeks between baseline, after the end of protocol treatment, and 12 weeks after treatment completion

  11. Assessment of metabolic syndrome

    Metabolic syndrome (polymetabolic syndrome, syndrome X, insulin resistance syndrome, Reaven syndrome) - a set of interrelated factors significantly increasing the risk of atherosclerosis and type 2 diabetes, as well as their vascular complications.

    Abdominal (central) obesity

    At least three of the following five abnormalities must be identified to formulate a diagnosis:

    abdominal obesity (waist circumference in men from Europe ≥ 94 cm, and in women ≥ 80 cm) and additionally co-existing two of the following abnormalities: triglycerides ≥ 150 mg/dl or dyslipidaemia related treatment cholesterol HDL < 40 mg/dl in males < 50 mg/dl in females or dyslipidaemia related treatment arterial pressure ≥ 130/85 mm Hg or arterial pressure related treatment fasting glycaemia ≥ 100 mg/dl or type 2 diabetes treatment

    Measured: at 5 weeks between baseline, after the end of protocol treatment

  12. Changes in blood parameter: TG

    Blood for the tests was drawn from basilic vein by medical personnel at the Rehabilitation Clinic.

    TG level:

    Below 150mg / dL (1.69mmol / L) Norm 150 - 199 mg / dL (1.69 - 2.25 mmol / L) Limit 200 - 499 mg / dL (2.26 - 5.63 mmol / L) High Above 500 mg / dL (5.64 mmol / L) Very high

    Measured: at 5 weeks between baseline, after the end of protocol treatment,

  13. Changes in blood parameter: atherogenic index

    Blood for the tests was drawn from basilic vein by medical personnel at the Rehabilitation Clinic.

    atherogenic index level

    • in men below 4.5 (below 3.5 after myocardial infarction)
    • in women below 4.0 (below 3.0 after myocardial infarction)

    Measured: at 5 weeks between baseline, after the end of protocol treatment,

  14. Changes in blood parameter: CRP

    Blood for the tests was drawn from basilic vein by medical personnel at the Rehabilitation Clinic.

    CRP level:

    • CRP below 5 mg / l (up to 10 mg / l - in obese people with hypertension) norm
    • CRP above 40 mg / l - may indicate a mild viral infection or pregnancy;
    • CRP above 200 mg / l - bacterial inflammation develops in the body;
    • CRP above 500 mg / l - takes place in the situation of very serious infections with basic and bacterial infections and burns.

    Measured: at 5 weeks between baseline, after the end of protocol treatment,

  15. Changes in blood parameter: serum glucose

    Blood for the tests was drawn from basilic vein by medical personnel at the Rehabilitation Clinic.

    serum glucose level: From 70 to 99 mg / dL (from 3.9 to 5.5 mmol / L) Normal glucose level From 100 to 125 mg / dL (from 5.6 to 6.9 mmol / L) Abnormal fasting glucose (pre-diabetes) From 126 mg / dL (7.0 mmol / L) Diabetes

    Measured: at 5 weeks between baseline, after the end of protocol treatment,

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Oct 2018
  2. Study startJun 2015
  3. Primary completionMar 2017
  4. Study completionMar 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
100 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03722602
Sponsor's protocol ID
Stroke-BodyComposition
Status last verified
Oct 2018
First submitted
22 May 2018
Last updated
30 Oct 2018
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Standard rehabilitation after stroke in people with Rehabilitation and Stroke, run by University of Rzeszow at 1 site in Poland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 30 Oct 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change Body composition assessment (fat mass, visceral fat level , muscle tissue, fat free mass , water content in the body) subjected to bioelectrical impedancy analysis - Tanita 780. (time frame: at baseline, immediately after treatment completion, and 12 weeks after treatment completion). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Oct 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in